記住我
Patients with advanced-stage urothelial carcinoma (UC) typically receive cisplatin-based chemotherapy, which confers a median overall survival (OS) duration of around 14 months. However, not all patients are deemed eligible to receive cisplatin, necessitating treatment with less-effective chemotherapies, such as carboplatin or immune-checkpoint inhibitor monotherapy. Now, data from a phase Ib/II trial suggest the superiority of the nectin-4-targeted antibody–drug conjugate enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients.
留言 (0)